Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
Olav Mella
(section)
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==Notable ME/CFS Studies== *2011, Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study<ref name="Fluge, 2011">{{Cite journal | last1 = Fluge | first1 = Øystein | authorlink1 = Øystein Fluge | last2 = Bruland | first2 = Ove | authorlink2 =| last3 = Risa | first3 = Kristin | authorlink3 = | last4 = Storstein | first4 = Anette| authorlink4 = | last5 = Kristoffersen | first5 = Einar Klæboe| authorlink5 =| last6 = Sapkota | first6 = Dipak | authorlink6 =| last7 = Næss | first7 = Halvor| authorlink7 =| last8 =Dahl | first8 = Olav| authorlink8 = | last9 = Nyland | first9 = Harald Inge | authorlink9 = | last10 = Mella | first10 = Olav | authorlink10 = Olav Mella | title = Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. | journal = PLoS One| volume = 6 | issue = 10 | page = e26358 | date = 2011 | pmid =| pmc = | doi= 10.1371/journal.pone.0026358}}</ref> - [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026358 (Full Text)] *2015, [[B cell|B-lymphocyte]] depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with [[rituximab]] maintenance treatment<ref name="Fluge2015-II">Fluge, Ø ; Risa, K ; Lunde, S; Alme, K ; Rekeland, IG; Sapkota, D; Kristoffersen, EK; Sørland, K; Bruland, O; Dahl, O; Mella, O. 2015. B-lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment. ''PLoS One,10''(7):e0129898. doi: 10.1371/journal.pone.0129898</ref> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488509/ (Full Text)] *2016, Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome<ref name="Fluge, 2016">{{Cite journal | last1 = Fluge | first1 = Øystein | authorlink1 = Øystein Fluge | last2 = Mella | first2 = Olav| authorlink2 = Olav Mella | last3 = Bruland | first3 = Ove | authorlink3 = | last4 = Risa | first4 = Kristin | authorlink4 = | last5 = Dyrstad | first5 = Sissel E. | authorlink5 =| last6 = Alme | first6 = Kine| authorlink6 =| last7 = Rekeland | first7 = Ingrid G. | authorlink7 =| last8 =Sapkota | first8 = Dipak | authorlink8 = | last9 = Røsland | first9 = Gro V. | authorlink9 = | last10 = Fosså | first10 = Alexander | authorlink10 = | last11 = Ktoridou-Valen | first11 = Irini | authorlink11 = | last12 = Lunde | first12 = Sigrid | authorlink12 = | last13 = Sørland | first13 = Kari | authorlink13 = | last14 =Lien | first14 = Katarina| authorlink14 = | last15 = Herder | first15 = Ingrid | authorlink15 = | last16 = Thürmer | first16 = Hanne| authorlink16 = | last17 = Gotaas | first17 = Merete E. | authorlink17 = | last18 = Baranowska | first18 = Katarzyna A. | authorlink18 = | last19 = Bohnen | first19 = Louis M.L.J. | authorlink19 = | last20 = Schäfer | first20 = Christoph | authorlink20 = | last21 = McCann | first21 = Adrian | authorlink21 = | last22 = Sommerfelt | first22 = Kristian | authorlink22 = | last23 = Helgeland | first23 = Lars | authorlink23 = | last24 = Ueland | first24 = Per M. | authorlink24 = | last25 = Dahl | first25 = Olav | authorlink25 = | last26 = Tronstad | first26 = Karl J. | authorlink26 = Karl Tronstad| title = Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome| journal = JCI Insight | volume = 1 | issue =21| pages = | date = 2016 | pmid = | doi= 10.1172/jci.insight.89376 | url=https://doi.org/10.1172/jci.insight.89376 | page = }}</ref> [https://insight.jci.org/articles/view/89376 (Full Text)] *2016, Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.<ref name="Lunde2016">[https://doi.org/10.1371/journal.pone.0161226 Lunde S, Kristoffersen EK, Sapkota D, Risa K, Dahl O, Bruland O, et al. (2016) Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome. PLoS ONE 11(8): e0161226. doi:10.1371/journal.pone.0161226]</ref> *2016, Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome<ref name="Loebel2016">{{Cite journal | last1 = Loebel | first1 = M | authorlink1 = Madlen Loebel | last2 = Grabowski | first2 = P | authorlink2 = Patricia Grabowski | last3 = Heidecke | first3 = H | authorlink3 = | last4 = Bauer | first4 = S | authorlink4 = | last5 = Hanitsch | first5 = LG | authorlink5 =| last6 = Wittke | first6 = K | authorlink6 =| last7 = Meisel | first7 = C | authorlink7 =| last8 =Reinke | first8 = P | authorlink8 = | last9 = Volk | first9 = H | authorlink9 = | last10 = Fluge | first10 = Ø| authorlink10 = Øystein Fluge | last11 = Mella | first11 = O | authorlink11 = Olav Mella | last12 = Scheibenbogen | first12 = C | authorlink12 = Carmen Scheibenbogen| title = Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome | url = https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-015-0628-4| journal = Brain, behavior, and immunity | volume = 52 | issue = | pages = 32-39 | pmid = 26399744 | date = 2016 | doi= 10.1016/j.bbi.2015.09.013}}</ref> - [https://www.sciencedirect.com/science/article/pii/S0889159115300209?via%3Dihub (Full Text)] *2018, Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)<ref>{{Cite journal | last = Günther | first = Oliver P. | last2 = Gardy | first2 = Jennifer L. | last3 = Stafford | first3 = Phillip | authorlink3 = Phillip Stafford | last4 = Fluge | first4 = Øystein | authorlink4 = Øystein Fluge | last5 = Mella | first5 = Olav | authorlink5 = Olav Mella | last6 = Tang | first6 = Patrick | last7 = Miller | first7 = Ruth R. | last8 = Parker | first8 = Shoshana M. | last9 = Johnston | first9 = Stephen A. | date = 2018-10-08 | title = Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)|url=https://link.springer.com/article/10.1007%2Fs12035-018-1354-8|journal=Molecular Neurobiology|language=en|volume=|pages=|doi=10.1007/s12035-018-1354-8|issn=0893-7648|via=}}</ref> [https://link.springer.com/article/10.1007/s12035-018-1354-8 (Full text)] *2018, Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome<ref>{{Cite journal | last = Schjøtt | first = Jan | authorlink = | last2 = Vries | first2 = Annick de | authorlink2 = | last3 = Mella | first3 = Olav | authorlink3 = Olav Mella | last4 = Sørland | first4 = Kari | authorlink4 = | last5 = Risa | first5 = Kristin | authorlink5 = | last6 = Alme | first6 = Kine | last7 = Fluge | first7 = Øystein | authorlink7 = Øystein Fluge | last8 = Rekeland | first8 = Ingrid G. | date = 2018-11-28 | title = Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome|url=https://www.clinicaltherapeutics.com/article/S0149-2918(18)30514-9/abstract|journal=Clinical Therapeutics|language=English|volume=0|issue=0|pages=|doi=10.1016/j.clinthera.2018.10.019|issn=1879-114X|pmid=30502905|quote=|via=}}</ref> [https://www.sciencedirect.com/science/article/abs/pii/S0149291818305149 (Abstract)] *2019, B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial<ref>{{Cite journal | last = Fluge | first = Øystein | authorlink = Øystein Fluge | last2 = Rekeland | first2 = Ingrid G. | last3 = Lien | first3 = Katarina | last4 = Thürmer | first4 = Hanne | last5 = Borchgrevink | first5 = Pette C. | last6 = Schäfer | first6 = Christoph | last7 = Sørland | first7 = Kari | last8 = Aßmus | first8 = Jörg | last9 = Ktoridou-Valen | first9 = Irini | last10 = Mella | first10 = Olav | authorlink10 = Olav Mella | date = 2019-04-02 | title = B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial|url=http://annals.org/article.aspx?doi=10.7326/M18-1451|journal=Annals of Internal Medicine|language=en|doi=10.7326/M18-1451|issn=0003-4819}}</ref> *2020, Human Leukocyte Antigen alleles associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)<ref name="Asgeir2020">{{Cite journal | last = Lande | first = Asgeir | authorlink = Asgeir Lande | last2 = Fluge | first2 = Øystein | authorlink2 = Øystein Fluge | last3 = Strand | first3 = Elin B. | authorlink3 = Elin Strand | last4 = Flåm | first4 = Siri T. | authorlink4=Siri Flåm | last5 = Sosa | first5 = Daysi D. | authorlink5 = Daysi Sosa | last6 = Mella | first6 = Olav | authorlink6 = Olav Mella | last7 = Egeland | first7 = Torstein | authorlink7 = | last8 = Saugstad | first8 = Ola D. | authorlink8 = | last9 = Lie | first9 = Benedicte A. | authorlink9 = | date = 2020-03-24 | title = Human Leukocyte Antigen alleles associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)|url=https://www.nature.com/articles/s41598-020-62157-x|journal=Scientific Reports|language=en|volume=10|issue=1|pages=1–8|doi=10.1038/s41598-020-62157-x|issn=2045-2322|pmc=|pmid=|access-date=|quote=|via=}}</ref> - [https://www.nature.com/articles/s41598-020-62157-x (Full text)] * 2020, Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study<ref name="Rekeland2020">{{Cite journal | last = Rekeland | first = Ingrid G. | authorlink = Ingrid Rekeland | last2 = Fosså | first2 = Alexander | authorlink2 = | last3 = Lande | first3 = Asgeir | authorlink3 = | last4 = Ktoridou-Valen | first4 = Irini | authorlink4 = | last5 = Sørland | first5 = Kari | authorlink5 = | last6 = Holsen | first6 = Mari | authorlink6 = | last7 = Tronstad | first7 = Karl J. | authorlink7 = Karl Tronstad | last8 = Risa | first8 = Kristin | authorlink8 = | last9 = Alme | first9 = Kine | authorlink9 = | date = 2020 | title=Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study|url=https://www.frontiersin.org/articles/10.3389/fmed.2020.00162/full|journal=Frontiers in Medicine|language=English|volume=7|issue=|pages=162|pmc=PMC7201056|pmid=32411717|doi=10.3389/fmed.2020.00162|issn=2296-858X|quote=|via= | last10 = Viken | first10 = Marte K. | authorlink10 = | last11 = Lie | first11 = Benedicte K. | authorlink11 = | last12 = Dahl | first12 = Olav | authorlink12 = | last13 = Mella | first13 = Olav | authorlink13 = Olav Mella | first14 = Øystein | last14 = Fluge | author-link14 = Øystein Fluge}}</ref> - [https://www.frontiersin.org/articles/10.3389/fmed.2020.00162/full? (Full text)] *2021, Fine mapping of the major histocompatibility complex (MHC) in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) suggests involvement of both HLA class I and class II loci<ref name="Hajdarevic2021">{{Cite journal | last = Hajdarevic | first = Riad | authorlink = Riad Hajdarevic | last2 = Lande | first2 = Asgeir | authorlink2 = Asgeir Lande | last3 = Rekeland | first3 = Ingrid | authorlink3 = Ingrid Rekeland | last4 = Rydland | first4 = Anne | authorlink4 = Anne Rydland | last5 = Strand | first5 = Elin B. | authorlink5 = | last6 = Sosa | first6 = Daisy D. | authorlink6 = | last7 = Creary | first7 = Lisa E | last8 = Mella | first8 = Olav | authorlink8 = Olav Mella | last9 = Egeland | first9 = Torstein | authorlink9 = Egeland Torstein | date = 2021-11-01 | title = Fine mapping of the major histocompatibility complex (MHC) in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) suggests involvement of both HLA class I and class II loci|url=https://www.sciencedirect.com/science/article/pii/S0889159121005092|journal=Brain, Behavior, and Immunity|language=en|volume=98|issue=|pages=101–109|doi=10.1016/j.bbi.2021.08.219|issn=0889-1591|pmc=|pmid=|access-date=|quote=|via=}}</ref>[https://doi.org/10.1016/j.bbi.2021.08.219 (Full text)]
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs